2024-01-012024-12-312024-12-31false09903467OXFORD MEDICAL DEVICES LIMITED2025-03-1974909falseiso4217:GBPxbrli:pure099034672024-01-01099034672024-12-31099034672024-01-012024-12-31099034672023-01-01099034672023-12-31099034672023-01-012023-12-3109903467bus:SmallEntities2024-01-012024-12-3109903467bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3109903467bus:AbridgedAccounts2024-01-012024-12-3109903467bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109903467core:WithinOneYear2024-12-3109903467core:AfterOneYear2024-12-3109903467core:WithinOneYear2023-12-3109903467core:AfterOneYear2023-12-3109903467core:ShareCapital2024-12-3109903467core:SharePremium2024-12-3109903467core:RevaluationReserve2024-12-3109903467core:OtherReservesSubtotal2024-12-3109903467core:RetainedEarningsAccumulatedLosses2024-12-3109903467core:ShareCapital2023-12-3109903467core:SharePremium2023-12-3109903467core:RevaluationReserve2023-12-3109903467core:OtherReservesSubtotal2023-12-3109903467core:RetainedEarningsAccumulatedLosses2023-12-3109903467core:LandBuildings2024-12-3109903467core:PlantMachinery2024-12-3109903467core:Vehicles2024-12-3109903467core:FurnitureFittings2024-12-3109903467core:OfficeEquipment2024-12-3109903467core:NetGoodwill2024-12-3109903467core:IntangibleAssetsOtherThanGoodwill2024-12-3109903467core:ListedExchangeTraded2024-12-3109903467core:UnlistedNon-exchangeTraded2024-12-3109903467core:LandBuildings2023-12-3109903467core:PlantMachinery2023-12-3109903467core:Vehicles2023-12-3109903467core:FurnitureFittings2023-12-3109903467core:OfficeEquipment2023-12-3109903467core:NetGoodwill2023-12-3109903467core:IntangibleAssetsOtherThanGoodwill2023-12-3109903467core:ListedExchangeTraded2023-12-3109903467core:UnlistedNon-exchangeTraded2023-12-3109903467core:LandBuildings2024-01-012024-12-3109903467core:PlantMachinery2024-01-012024-12-3109903467core:Vehicles2024-01-012024-12-3109903467core:FurnitureFittings2024-01-012024-12-3109903467core:OfficeEquipment2024-01-012024-12-3109903467core:NetGoodwill2024-01-012024-12-3109903467core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109903467core:ListedExchangeTraded2024-01-012024-12-3109903467core:UnlistedNon-exchangeTraded2024-01-012024-12-3109903467core:MoreThanFiveYears2024-01-012024-12-3109903467core:Non-currentFinancialInstruments2024-12-3109903467core:Non-currentFinancialInstruments2023-12-3109903467dpl:CostSales2024-01-012024-12-3109903467dpl:DistributionCosts2024-01-012024-12-3109903467core:LandBuildings2024-01-012024-12-3109903467core:PlantMachinery2024-01-012024-12-3109903467core:Vehicles2024-01-012024-12-3109903467core:FurnitureFittings2024-01-012024-12-3109903467core:OfficeEquipment2024-01-012024-12-3109903467dpl:AdministrativeExpenses2024-01-012024-12-3109903467core:NetGoodwill2024-01-012024-12-3109903467core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3109903467dpl:GroupUndertakings2024-01-012024-12-3109903467dpl:ParticipatingInterests2024-01-012024-12-3109903467dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3109903467core:ListedExchangeTraded2024-01-012024-12-3109903467dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3109903467core:UnlistedNon-exchangeTraded2024-01-012024-12-3109903467dpl:CostSales2023-01-012023-12-3109903467dpl:DistributionCosts2023-01-012023-12-3109903467core:LandBuildings2023-01-012023-12-3109903467core:PlantMachinery2023-01-012023-12-3109903467core:Vehicles2023-01-012023-12-3109903467core:FurnitureFittings2023-01-012023-12-3109903467core:OfficeEquipment2023-01-012023-12-3109903467dpl:AdministrativeExpenses2023-01-012023-12-3109903467core:NetGoodwill2023-01-012023-12-3109903467core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3109903467dpl:GroupUndertakings2023-01-012023-12-3109903467dpl:ParticipatingInterests2023-01-012023-12-3109903467dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3109903467core:ListedExchangeTraded2023-01-012023-12-3109903467dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3109903467core:UnlistedNon-exchangeTraded2023-01-012023-12-3109903467core:NetGoodwill2024-12-3109903467core:IntangibleAssetsOtherThanGoodwill2024-12-3109903467core:LandBuildings2024-12-3109903467core:PlantMachinery2024-12-3109903467core:Vehicles2024-12-3109903467core:FurnitureFittings2024-12-3109903467core:OfficeEquipment2024-12-3109903467core:AfterOneYear2024-12-3109903467core:WithinOneYear2024-12-3109903467core:ListedExchangeTraded2024-12-3109903467core:UnlistedNon-exchangeTraded2024-12-3109903467core:ShareCapital2024-12-3109903467core:SharePremium2024-12-3109903467core:RevaluationReserve2024-12-3109903467core:OtherReservesSubtotal2024-12-3109903467core:RetainedEarningsAccumulatedLosses2024-12-3109903467core:NetGoodwill2023-12-3109903467core:IntangibleAssetsOtherThanGoodwill2023-12-3109903467core:LandBuildings2023-12-3109903467core:PlantMachinery2023-12-3109903467core:Vehicles2023-12-3109903467core:FurnitureFittings2023-12-3109903467core:OfficeEquipment2023-12-3109903467core:AfterOneYear2023-12-3109903467core:WithinOneYear2023-12-3109903467core:ListedExchangeTraded2023-12-3109903467core:UnlistedNon-exchangeTraded2023-12-3109903467core:ShareCapital2023-12-3109903467core:SharePremium2023-12-3109903467core:RevaluationReserve2023-12-3109903467core:OtherReservesSubtotal2023-12-3109903467core:RetainedEarningsAccumulatedLosses2023-12-3109903467core:NetGoodwill2023-01-0109903467core:IntangibleAssetsOtherThanGoodwill2023-01-0109903467core:LandBuildings2023-01-0109903467core:PlantMachinery2023-01-0109903467core:Vehicles2023-01-0109903467core:FurnitureFittings2023-01-0109903467core:OfficeEquipment2023-01-0109903467core:AfterOneYear2023-01-0109903467core:WithinOneYear2023-01-0109903467core:ListedExchangeTraded2023-01-0109903467core:UnlistedNon-exchangeTraded2023-01-0109903467core:ShareCapital2023-01-0109903467core:SharePremium2023-01-0109903467core:RevaluationReserve2023-01-0109903467core:OtherReservesSubtotal2023-01-0109903467core:RetainedEarningsAccumulatedLosses2023-01-0109903467core:AfterOneYear2024-01-012024-12-3109903467core:WithinOneYear2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:CostValuation2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-012024-12-3109903467core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3109903467core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3109903467core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3109903467core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3109903467core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3109903467bus:Director12024-01-012024-12-3109903467bus:Director22024-01-012024-12-31

OXFORD MEDICAL DEVICES LIMITED

Registered Number
09903467
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2024

OXFORD MEDICAL DEVICES LIMITED
Company Information
for the year from 1 January 2024 to 31 December 2024

Directors

GOULD, Magdalena Katarzyna
GOULD, Marcus, Dr

Registered Address

Unit 1, Pearl Assurance House
Elbow Lane
Tavistock
PL19 0BG

Registered Number

09903467 (England and Wales)
OXFORD MEDICAL DEVICES LIMITED
Balance Sheet as at
31 December 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets32,4032,038
2,4032,038
Current assets
Debtors25,84210,362
Cash at bank and on hand235,088224,069
260,930234,431
Creditors amounts falling due within one year4(37,602)(68,080)
Net current assets (liabilities)223,328166,351
Total assets less current liabilities225,731168,389
Net assets225,731168,389
Capital and reserves
Called up share capital1212
Profit and loss account225,719168,377
Shareholders' funds225,731168,389
The financial statements were approved and authorised for issue by the Board of Directors on 19 March 2025, and are signed on its behalf by:
GOULD, Magdalena Katarzyna
Director
Registered Company No. 09903467
OXFORD MEDICAL DEVICES LIMITED
Notes to the Financial Statements
for the year ended 31 December 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
2.Average number of employees

20242023
Average number of employees during the year22
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 January 245,975
Additions1,867
At 31 December 247,842
Depreciation and impairment
At 01 January 243,938
Charge for year1,501
At 31 December 245,438
Net book value
At 31 December 242,403
At 31 December 232,038
4.Creditors: amounts due within one year

2024

2023

££
Taxation and social security36,47932,018
Other creditors46335,462
Accrued liabilities and deferred income660600
Total37,60268,080
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.